Published online Nov 15, 2016. doi: 10.4251/wjgo.v8.i11.793
Peer-review started: June 17, 2016
First decision: July 30, 2016
Revised: August 1, 2016
Accepted: August 30, 2016
Article in press: August 31, 2016
Published online: November 15, 2016
Core tip: The choice of colorectal cancer (CRC) screening methods is crucial for screening validity and compliance. Currently, the fecal immunochemical test (FIT), fecal DNA and the blood-based SEPT9 assays are the three in vitro diagnostic tests for CRC screening. In this article, we reviewed the current application of the three types of assays and compared their performance in CRC screening. FIT is still the cheapest method with high screening validity, and fecal DNA tests also exhibit high validity but its price is high. In contrast, the SEPT9 assay showed high compliance with acceptable performance. The choice of screening test may depend on the balance of performance, compliance and costs.